TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma. - Qiu, Dongbo; Wang, Tiantian; Xiong, Yi; Li, Kun; Qiu, Xiusheng; Feng, Yuan; Lian, Qinghai; Qin, Yunfei; Liu, Kunpeng; Zhang, Qi; Jia, Changchang (Oncogenesis, 2024)